Acumen Pharmaceuticals マネジメント
マネジメント 基準チェック /44
Acumen Pharmaceuticalsの CEO はDan O'Connellで、 Dec2014年に任命され、 の在任期間は 11.42年です。 の年間総報酬は$ 1.86Mで、 34.7%給与と65.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.41%を直接所有しており、その価値は$ 746.83K 。経営陣と取締役会の平均在任期間はそれぞれ4.5年と6.5年です。
主要情報
Dan O'Connell
最高経営責任者
US$1.9m
報酬総額
| CEO給与比率 | 34.68% |
| CEO在任期間 | 11.4yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 4.5yrs |
| 取締役会の平均在任期間 | 6.5yrs |
経営陣の近況
Recent updates
新しいナラティブ • May 17
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?分析記事 • Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 30
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug’s Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease. Acumen Pharmaceuticals has a healthy cash runway, estimated at 3.5 years, and appears undervalued relative to its peers in the biotech sector. Despite the promising data, investing in ABOS is speculative due to the early stages of research and the potential long timeline to FDA approval. Read the full article on Seeking Alpha分析記事 • Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 28
Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
The shares of microcap biotech Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) more than doubled in value on Wednesday after its rivals Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab. In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday. With data validating the amyloid hypothesis in Alzheimer's, developers with similar drugs in their pipeline surged in value. Acumen (ABOS) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023. ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.Seeking Alpha • Jun 30
Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other Alzheimer's therapies in development -- and marketed ones such as Biogen's (BIIB) Aduhelm (aducanumab) -- that target the removal of beta amyloid plaque from the brain, ACU193 works differently as a anti-amyloid-beta oligomer (AβO) monoclonal antibody. Analyst Andrew Fein noted that ACU193 "lacks the inflammatory effector functions of other [immunoglobulin] subclasses, thereby making it less prone to [amyloid-related imaging abnormalities], a major safety issue with current anti-[amyloid beta] therapies. Acumen (ABOS) said ACU193 prevents toxic AβOs from binding to dendritic spines and preserves neural function. The company added the candidate has the potential for disease slowing as well as cognitive improvement. The ongoing phase 1 trial is expected to enroll 62 subjects with mild cognitive impairment or mild dementia.分析記事 • May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$113m |
| Dec 31 2025 | US$2m | US$646k | -US$121m |
| Sep 30 2025 | n/a | n/a | -US$133m |
| Jun 30 2025 | n/a | n/a | -US$137m |
| Mar 31 2025 | n/a | n/a | -US$116m |
| Dec 31 2024 | US$5m | US$621k | -US$102m |
| Sep 30 2024 | n/a | n/a | -US$82m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$56m |
| Dec 31 2023 | US$4m | US$598k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$3m | US$570k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$1m | US$525k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$92m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$336k | US$240k | -US$7m |
報酬と市場: Danの 総報酬 ($USD 1.86M ) は、 US市場 ($USD 1.66M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Danの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Dan O'Connell (54 yo)
11.4yrs
在職期間
US$1,863,567
報酬
Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. sin...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 11.4yrs | US$1.86m | 0.41% $ 746.8k | |
| President & Chief Development Officer | 2.3yrs | US$1.01m | 0.017% $ 31.5k | |
| CFO & Chief Business Officer | 5yrs | US$948.79k | 0.17% $ 316.1k | |
| Co-Founder | 30.3yrs | US$42.00k | データなし | |
| Co-Founder | no data | データなし | データなし | |
| Co-Founder | no data | データなし | データなし | |
| Chief Operating Officer | 5.3yrs | US$223.68k | 0.087% $ 158.0k | |
| Senior Vice President of Finance & Accounting and Corporate Controller | 2.8yrs | データなし | データなし | |
| VP & Head of Investor Relations | 3.7yrs | データなし | データなし | |
| Chief Legal Officer & Corporate Secretary | 3.7yrs | US$1.48m | 0% $ 0 | |
| Associate Director of Communications | 4yrs | データなし | データなし | |
| Chief People Officer | 5.3yrs | データなし | データなし |
4.5yrs
平均在職期間
55.5yo
平均年齢
経験豊富な経営陣: ABOSの経営陣は 経験豊富 であると考えられます ( 4.5年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 20.1yrs | US$1.86m | 0.41% $ 746.8k | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 7.6yrs | US$107.05k | 0.42% $ 762.8k | |
| Independent Director | 4.1yrs | US$89.11k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 12yrs | US$79.11k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし | |
| Chairman of the Board | less than a year | US$82.74k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$84.61k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | データなし | データなし |
6.5yrs
平均在職期間
68yo
平均年齢
経験豊富なボード: ABOSの 取締役会 は 経験豊富 であると考えられます ( 6.5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 17:12 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Acumen Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |